13F Insight
DOSSIER · 13F-HR · Q1 2026

FARALLON CAPITAL MANAGEMENT LLC

$21.2B in tracked AUM across 151 positions as of Q1 2026.

FC
CIK 0000909661 · last filed Mar 31, 2026
Total AUM
$21.2B
as of Q1 2026
Holdings
151
—
positions
Whale Score
73
73
strong
Activity
—
no data
changes this Q
AI Analysis · Q1 2026

FARALLON CAPITAL MANAGEMENT LLC filed Q1 2026 13F-HR with $21.2B in disclosed U.S. equity holdings The portfolio is led by Healthcare exposure, with top positions including 78462F953 (8.5%), RVMD (7.5%), AMZN (5.0%). Quarter-over-quarter activity shows 50 new entries and 2 exits, with a net additive posture across 52 changed positions. Notable new position: 78462F953 $$0.0B.

FARALLON CAPITAL MANAGEMENT LLC reports $21.2B in U.S. equity holdings for Q1 2026, anchored by a Healthcare-centric allocation. The top five positions by value span 78462F953 + RVMD + AMZN + MSFT + G0403H108, collectively representing a meaningful concentration within the disclosed book.

Core Holdings

  • 78462F953 (STATE STR SPDR S&P 500 ETF T) — $1.5B (8.5%)
  • RVMD (REVOLUTION MEDICINES INC) — $1.3B (7.5%)
  • AMZN (AMAZON COM INC) — $0.9B (5.0%)
  • MSFT (MICROSOFT CORP) — $0.9B (4.9%)
  • G0403H108 (AON PLC) — $0.8B (4.6%)

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
78462F953
STATE STR SPDR S&P 500 ETF T
$1.5B2.3M8.5%02
RVMD
REVOLUTION MEDICINES INC
$1.3B13.6M7.5%03
AMZN
AMAZON COM INC
$879M4.2M5.0%04
MSFT
MICROSOFT CORP
$868M2.3M4.9%05
G0403H108
AON PLC
$811M2.5M4.6%06
BBIO
BRIDGEBIO PHARMA INC
$695M9.4M4.0%07
46137V957
INVESCO EXCHANGE TRADED FD T
$691M3.6M3.9%08
PTGX
PROTAGONIST THERAPEUTICS INC
$669M6.3M3.8%09
NTRA
NATERA INC
$641M3.2M3.7%10
EXEL
EXELIXIS INC
$562M13.1M3.2%

Filing history

2026Q1Mar 31
$17.5B▼ 20.5%
172 positionsView →2025Q4Dec 31
$22.1B▼ 9.6%
153 positionsView →2025Q3Sep 30
$24.4B▲ 4.8%
144 positionsView →2025Q2Jun 30
$23.3B▲ 128.0%
142 positionsLocked2025Q1Mar 31
$10.2B▼ 48.4%
91 positionsLocked2024Q4Dec 31
$19.8B▼ 5.6%
139 positionsLocked2024Q3Sep 30
$21.0B▼ 3.1%
155 positionsLocked2024Q2Jun 30
$21.6B▼ 2.8%
159 positionsLocked2024Q1Mar 31
$22.3B▲ 4.8%
170 positionsLocked2023Q4Dec 31
$21.2B▼ 0.7%
155 positionsLocked2023Q3Sep 30
$21.4B▲ 7.3%
163 positionsLocked2023Q2Jun 30
$19.9B▲ 8.8%
173 positionsLocked
Showing 12 of 100